Routine HIV Screening in France: Clinical Impact and Cost-Effectiveness

DSpace/Manakin Repository

Routine HIV Screening in France: Clinical Impact and Cost-Effectiveness

Citable link to this page

. . . . . .

Title: Routine HIV Screening in France: Clinical Impact and Cost-Effectiveness
Author: Yazdanpanah, Yazdan; Sloan, Caroline E.; Charlois-Ou, Cécile; Le Vu, Stéphane; Semaille, Caroline; Costagliola, Dominique; Pillonel, Josiane; Poullié, Anne-Isabelle; Scemama, Olivier; Deuffic-Burban, Sylvie; Paltiel, A. David; Losina, Elena; Walensky, Rochelle P.; Freedberg, Kenneth Alan

Note: Order does not necessarily reflect citation order of authors.

Citation: Yazdanpanah, Yazdan, Caroline E. Sloan, Cécile Charlois-Ou, Stéphane Le Vu, Caroline Semaille, Dominique Costagliola, Josiane Pillonel, et al. 2010. Routine HIV Screening in France: Clinical Impact and Cost-Effectiveness. PLoS ONE 5(10): e13132.
Full Text & Related Files:
Abstract: Background: In France, roughly 40,000 HIV-infected persons are unaware of their HIV infection. Although previous studies have evaluated the cost-effectiveness of routine HIV screening in the United States, differences in both the epidemiology of infection and HIV testing behaviors warrant a setting-specific analysis for France. Methods/Principal Findings: We estimated the life expectancy (LE), cost and cost-effectiveness of alternative HIV screening strategies in the French general population and high-risk sub-populations using a computer model of HIV detection and treatment, coupled with French national clinical and economic data. We compared risk-factor-based HIV testing (“current practice”) to universal routine, voluntary HIV screening in adults aged 18–69. Screening frequencies ranged from once to annually. Input data included mean age (42 years), undiagnosed HIV prevalence (0.10%), annual HIV incidence (0.01%), test acceptance (79%), linkage to care (75%) and cost/test (€43). We performed sensitivity analyses on HIV prevalence and incidence, cost estimates, and the transmission benefits of ART. “Current practice” produced LEs of 242.82 quality-adjusted life months (QALM) among HIV-infected persons and 268.77 QALM in the general population. Adding a one-time HIV screen increased LE by 0.01 QALM in the general population and increased costs by €50/person, for a cost-effectiveness ratio (CER) of €57,400 per quality-adjusted life year (QALY). More frequent screening in the general population increased survival, costs and CERs. Among injection drug users (prevalence 6.17%; incidence 0.17%/year) and in French Guyana (prevalence 0.41%; incidence 0.35%/year), annual screening compared to every five years produced CERs of €51,200 and €46,500/QALY. Conclusions/Significance: One-time routine HIV screening in France improves survival compared to “current practice” and compares favorably to other screening interventions recommended in Western Europe. In higher-risk groups, more frequent screening is economically justifiable.
Published Version: doi:10.1371/journal.pone.0013132
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956760/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:4889579

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters